UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 02, 2026 |
AVITA Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-39059 |
85-1021707 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
28159 Avenue Stanford Suite 220 |
|
Valencia, California |
|
91355 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 661 367-9170 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share |
|
RCEL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On November 2, 2026, the Company lodged certain filings on the Australian Securities Exchange (the "ASX") disclosing the exercise by Perceptive Credit Holdings V, LP ("Perceptive") of the warrant certificate issued by the Company to Perceptive on June 5, 2026 (the “Warrant”). As previously disclosed, the Warrant was issued pursuant to that certain Credit Agreement and Guaranty, dated January 13, 2026, by and between Perceptive and the Company and was exercisable for up to 500,000 shares of Company common stock. Perceptive exercised the Warrant on October 26, 2026 via a cashless exercise whereby the Company withheld 112,284 shares covered by the Warrant in respect of the exercise price and issued the remaining 387,716 shares to Perceptive on October 28, 2026.
The filings were lodged on the ASX pursuant to ASX listing rules.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AVITA Medical, Inc. |
|
|
|
|
Date: |
November 2, 2026 |
By: |
/s/ David O'Toole |
|
|
|
Name: David O'Toole
Title: Chief Financial Officer |